Table 4

Assessments and their time schedule

Assessment and evaluation methodTime of measurement (months)
<0BL3612
Primary outcome
15D instrument*45 46QXXXX
Secondary outcomes
Occupational functioning
 Self-assessed work ability47QXXXX
 Job strain48 49QXX
 Need for Recovery (NRF)50QXXXX
Psychiatric symptoms
 Generalised Anxiety Disorder 7 (GAD-7)*51QXXXX
 Insomnia Severity Index (ISI)*52, In Finnish53QXXXX
 The Symptom Checklist-90 (SCL-90)*54 55 In Finnish56QXXXX
 The Patient Health Questionnaire (PHQ-9)57; In Finnish58QXXXX
Cognitive and emotional functioning
 The Acceptance and Action Questionnaire-II (AAQ-II)59 60 in Finnish, Tuomisto M. 2007 and 2011QXXXX
 Illness Worry Scale (IWS)61 62QXXXX
 Penn State Worry Questionnaire (PSWQ)63 in Finnish, Tuomisto M. 2002QXXXX
 Strategy and Attribution Questionnaire (SAQ)*64QXXX
Assessment of treatment alliance and satisfaction
 Working Alliance Inventory (WAI)†65 66Q
 Treatment satisfaction‡67QXXX
Background variables
Demographics (age, gender, marital status, education)QX
Clinical characteristics
 Health, diagnosed diseases and medicationQXX
 Alcohol Use Disorders Identification Test (Audit)*68QXX
 Asthma Control Test (ACT)§69QXX
 General symptomsQXXXXX
 Peak Expiratory Flow (PEF)-measurements for 2 weeks41LX
 Bronchial hyper-responsiveness40LX
 The Quick Environmental Exposure and Sensitivity Inventory (QEESI)70QXX
 Home environmentQXX
 Work characteristics and occupational functioningQXX
 The Holmes and Rahe stress scale71QXXX
Personality and social functioning functions
 Short Five (S5) personality inventory*72QX
 The Inventory of Interpersonal Problems (IIP)73QXX
 Sense of Coherence (SOC-13)*74QXX
  • *Psychometric properties of the Finnish population are good.

  • †In the Cognitive Behaviour Therapy arm, the participants and the psychotherapists fill the Working Alliance Inventory (WAI) after first, fifth and last (10th) session.

  • ‡In the psychoeducation arm, the participants answer the 5-question Treatment Satisfaction questionnaire.

  • §The Finnish version of the ACT. The ACT is a trademark of Quality Metric Incorporated 2002 GlaxoSmithKline.

  • BL, baseline; L, medical investigation; Q, questionnaire.